Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

The origins and consequences of a regulatory T cell (Treg) disorder in systemic lupus erythematosus (SLE) are poorly understood. In the (NZBxNZW) F1 mouse model of lupus, we found that CD4+Foxp3+ Treg failed to maintain a competitive pool size in the peripheral lymphoid organs resulting in a progressive homeostatic imbalance of CD4+Foxp3+ Treg and CD4+Foxp3− conventional T cells (Tcon). In addition, Treg acquired phenotypic changes that are reminiscent of IL-2 deficiency concomitantly to a progressive decline in IL-2-producing Tcon and an increase in activated, IFN-γ-producing effector Tcon. Nonetheless, Treg from lupus-prone mice were functionally intact and capable to influence the course of disease. Systemic reduction of IL-2 levels early in disease promoted Tcon hyperactivity, induced the imbalance of Treg and effector Tcon, and strongly accelerated disease progression. In contrast, administration of IL-2 partially restored the balance of Treg and effector Tcon by promoting the homeostatic proliferation of endogenous Treg and impeded the progression of established disease. Thus, an acquired and self-amplifying disruption of the Treg-IL-2 axis contributed essentially to Tcon hyperactivity and the development of murine lupus. The reversibility of this homeostatic Treg disorder provides promising approaches for the treatment of SLE.

[1]  L. Morel,et al.  Murine Models of Systemic Lupus Erythematosus , 2011, Journal of biomedicine & biotechnology.

[2]  A. Scheffold,et al.  IL‐2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells , 2008, European journal of immunology.

[3]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[4]  C. Baecher-Allan,et al.  Human regulatory T cells and autoimmunity , 2008, European journal of immunology.

[5]  B. Croker,et al.  Murine Lupus Susceptibility Locus Sle1a Controls Regulatory T Cell Number and Function through Multiple Mechanisms1 , 2007, The Journal of Immunology.

[6]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[7]  J. Rogers,et al.  Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity , 2007, Nature Genetics.

[8]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[9]  L. Morel,et al.  IL-6 Produced by Dendritic Cells from Lupus-Prone Mice Inhibits CD4+CD25+ T Cell Regulatory Functions1 , 2007, The Journal of Immunology.

[10]  J. Bluestone,et al.  Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells1 , 2006, The Journal of Immunology.

[11]  P. Debré,et al.  Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus1 , 2005, The Journal of Immunology.

[12]  J. Lohr,et al.  Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen , 2005, The Journal of experimental medicine.

[13]  L. Klein,et al.  Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling , 2005, Nature Immunology.

[14]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[15]  G. Riemekasten,et al.  Key autoantigens in SLE. , 2005, Rheumatology.

[16]  S. Sakaguchi Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[17]  C. Mawrin,et al.  Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. , 2005, The Journal of clinical investigation.

[18]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[19]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[20]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[21]  F. Huang,et al.  Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-β1 gene therapy using attenuated Salmonella typhimurium as gene carrier , 1999, Lupus.

[22]  J. Alcocer-Varela,et al.  Interleukin-2 and systemic lupus erythematosus—fifteen years later , 1998, Lupus.

[23]  R. Noelle,et al.  Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells , 1995, European journal of immunology.

[24]  H. Griesser,et al.  Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. , 1995, Science.

[25]  A. Feller,et al.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.

[26]  C. Martínez-A,et al.  Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus , 1990, Nature.

[27]  F. Ruscetti Biology of interleukin-2 , 1984, Survey of immunologic research.

[28]  S. Gendler,et al.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). , 1983, Journal of immunology.

[29]  D. Wofsy,et al.  Interleukin 2 deficiency is a common feature of autoimmune mice. , 1981, Journal of immunology.

[30]  O. Rosen,et al.  Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. , 2009, Blood.

[31]  G. Hoffmann,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .